


Data Sheet

Product Name:	LMT-28
Cat. No.:	CS-0022963
CAS No.:	1239600-18-0
Molecular Formula:	C ₁₇ H ₂₉ NO ₄
Molecular Weight:	311.42
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Solubility:	DMSO : 100 mg/mL (321.11 mM; Need ultrasonic)



BIOLOGICAL ACTIVITY:

LMT-28 is an orally active and the first synthetic **IL-6** inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130^[1]. **In Vitro:** LMT-28 reduces IL-6-induced luciferase activity by ~90% at a concentration of 50 μM and exhibits an IC₅₀ value of 5.9 μM. LMT-28 (1-10 μM; 72 hours) inhibits IL-6-induced proliferation of the human erythroleukemic cell line TF-1^[1].

LMT-28 (1-100 μM; 1 hour) selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130^[1]. **In Vivo:** LMT-28 (0-0.5 mg/kg; p.o.; once daily for 15 days) alleviates CIA in mice^[1].

LMT-28 (0.25 or 1 mg/kg; p.o.) ameliorates the progression of pancreatitis in mice. LMT-28 binds directly and specifically to gp130, and thereby inhibits the interaction of gp130 with the IL-6/IL-6Rα complex^[1].

References:

[1]. Hong SS, et al. A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor β Subunit, Glycoprotein 130. J Immunol. 2015 Jul 1;195(1):237-45.

CAIndexNames:

2-Oxazolidinone, 3-[(2S,3S)-3-hydroxy-2-methyl-4-methylene-1-oxonyl]-4-(1-methylethyl)-, (4S)-

SMILES:

O=C1OC[C@H](C(C)C)N1C([C@@H](C)[C@H](O)C(CCCCC)=C)=O

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA